HOPE Therapeutics Expands Florida Presence with Acquisition of Cohen & Associates

HOPE Therapeutics (NASDAQ: NRXP) has announced a significant expansion of its interventional psychiatry network through the acquisition of Cohen & Associates, a prominent practice based in Sarasota, Florida. This strategic move extends HOPE’s reach into Western Florida and Palm Beach.

As part of the acquisition, Dr. Rebecca Cohen, the founder of Cohen & Associates, has been appointed as HOPE’s Medical Director. In her new role, Dr. Cohen will be responsible for overseeing the medical standards of care across all of HOPE’s Florida locations. The deal is anticipated to positively contribute to HOPE’s overall revenue and EBITDA.

Established in 2014, Cohen & Associates is one of the nation’s pioneering practices dedicated to interventional psychiatry. The practice offers advanced treatments for depression, PTSD, and other central nervous system disorders, including ketamine therapy, Transcranial Magnetic Stimulation (TMS), and comprehensive medication management.

Dr. Cohen is a distinguished expert in interventional psychiatry and psychopharmacology, holding fellowships with both the American Psychiatric Association (APA) and the International Clinical TMS Society. Her deep knowledge, particularly in the application of TMS, aligns with HOPE’s existing clinical platform and enhances the company’s capacity for innovation and improved patient outcomes.

This expansion is a key component of HOPE’s strategy to develop a leading psychiatric care network. HOPE Therapeutics is owned by NRx Pharmaceuticals, which is advancing its own pipeline of NMDA-based drug candidates, NRX-100 and NRX-101, for treating suicidal depression and PTSD. The integration of a respected practice like Cohen & Associates strengthens HOPE’s position in the field of advanced neuropsychiatric care.

Several developments are expected to drive future momentum. NRx Pharmaceuticals is actively pursuing regulatory milestones for NRX-100, having recently filed a New Drug Application (NDA) and an application for the FDA’s National Priority Voucher Program. For HOPE Therapeutics, growth is expected from continued clinic expansion in Florida, revenue from the newly acquired practice, and the broader integration of ketamine and TMS treatments as reimbursement policies evolve.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently re-filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.